1.Prosthetic Valve Replacement Using Warm Heart Surgery for Mitral Valve Regurgitation in Childhood.
Tetsuro Takayama ; Takeshi Miyairi ; Kenji Koseni ; Nobuhiro Nagata
Japanese Journal of Cardiovascular Surgery 1995;24(2):108-111
In 4 children (2.4-10.9 y.o) with mitral valve regurgitation, prosthetic valve replacement was done using warm heart surgery. Three of them had previously received 1-3 times valve repair operations and the other one was accompanied by endocarditis. The condition of 3 children were in NYHA grade 4 and received dopamine preoperatively. At the esophageal temperature of 34 degree, aorta was cross clamped for 79-216min. with continuous coronary perfusion of 3ml/kg/min, however, no child showed postoperative low output syndrome, and the maximum use of dopamine was 2-6μg/kg/min and the CK-MB at 1POD was within the normal range in all cases. Warm heart surgery showed better myocardial protection for pediatric mitral valve replacement.
2.Prospective Clinical Trial of Intravitreal Aflibercept Treat-andextend Regimen for Diabetic Macular Edema: 1-Year Outcomes
Hiroki MIENO ; Kazuhito YONEDA ; Nobuhiro TERAO ; Kengo YOSHII ; Kentaro KOJIMA ; Kenji NAGATA ; Chie SOTOZONO
Korean Journal of Ophthalmology 2020;34(4):290-296
Purpose:
To investigate the efficacy of aflibercept for the treatment of diabetic macular edema via a treat-and-extend regimen.
Methods:
This prospective, single-center, open-label, interventional study involved 30 patients with a best-corrected visual acuity (BCVA) ≤0.6 and a central retinal thickness (CRT) ≥300 μm. The enrolled eyes each received a monthly intravitreal aflibercept injection until the CRT decreased below 300 μm, upon which the administration interval was extended for 1 month until the CRT once again increased to ≥300 μm. Main outcome measures were median BCVA and CRT at 6 and 12 months after initiation of treatment via last observation carried forward analysis, the median number of injections over the 12 months, and the effects on the diabetic retinopathy severity scale (DRSS) score of the patients who completed the 12-month follow-up period.
Results:
Of the 30 enrolled patients, 29 and 25 respectively completed the 6- and 12-month follow-up examinations. From baseline to 6 and 12 months after treatment initiation, the median BCVA (logarithm of the minimum angle of resolution) significantly improved from 0.52 to 0.30 and 0.35, respectively, and the median CRT significantly decreased from 439.5 to 268.5 and 249.0 μm, respectively. The median number of injections over the 12-month follow-up period was 6.0. Compared to baseline, the DRSS score at 12 months was improved by 2 steps in 16% of patients; in no cases did the DRSS score worsen or improve by three steps or more.
Conclusions
When administered in a treat-and-extend regimen, aflibercept is an effective treatment option for diabetic macular edema.
3.Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Yoko KUBUKI ; Kotaro SHIDE ; Takuro KAMEDA ; Takumi YAMAJI ; Masaaki SEKINE ; Ayako KAMIUNTEN ; Keiichi AKIZUKI ; Haruko SHIMODA ; Yuki TAHIRA ; Kenichi NAKAMURA ; Hiroo ABE ; Tadashi MIIKE ; Hisayoshi IWAKIRI ; Yoshihiro TAHARA ; Mitsue SUETA ; Kanna HASHIMOTO ; Shojiro YAMAMOTO ; Satoru HASUIKE ; Tomonori HIDAKA ; Kenji NAGATA ; Akira KITANAKA ; Kazuya SHIMODA
Annals of Laboratory Medicine 2017;37(2):159-161
No abstract available.
Adolescent
;
Adult
;
Age Factors
;
Aged
;
Aged, 80 and over
;
Amino Acid Sequence
;
Calreticulin/*genetics
;
Child
;
DNA/chemistry/genetics/metabolism
;
Exons
;
Female
;
Humans
;
Janus Kinase 2/*genetics
;
Male
;
Middle Aged
;
Molecular Sequence Data
;
Polymorphism, Single Nucleotide
;
Receptors, Thrombopoietin/genetics
;
Sequence Analysis, DNA
;
Sex Factors
;
Thrombocythemia, Essential/*diagnosis/genetics
;
Young Adult
4.Problems for uninsured traveler in availing medical treatment: Case study of a person who suffered cerebral infarction
Yoshihisa MATSUMOTO ; Yoshihiro TAKAYAMA ; Shin GOTO ; Takuro HASHIKAWA ; Yui NAGATA ; Hidenobu YOSHITAKE ; Hideki SAKAI ; Setsuko NAKAGAWA ; Kenji TAKAHASHI
Journal of International Health 2019;34(1):13-18
Background The number of foreign tourists visiting Japan has increased to about 30 million people per year. 1.5% of them were injured or became sick during their travelin Japan and had to undergo medical treatment. Among the foreign tourists, 27% were not covered by travel health insurance.Case A 40-year-old man from Southeast Asia who was visiting his relative in Japan experienced sudden hemiparesis and was diagnosed with cerebral infarction. During the initial treatment, it was found that the patient did not have health insurance and the relatives could not afford to pay the treatment costs. No other source of financial support was available to him During our consultations with the patient and his relatives about the medical treatment including medical expenses, he continued to be treated as an outpatient and it was aimed at an early return to his home country.Discussion Foreigners, who are not covered under travel health insurance, could fall ill or sustain an injury during their stay in Japan. Appropriate medical care should be provided regardless of their ability to pay. However, a situation that could lead them to incur huge medical expenses from availing medical care should be avoided. For medical consultations of non-insured foreigners, it is better to consult the available systems and pay attention about feasible medical expenses. There is a need for a long-term vision of medical care to make a smooth transition from medical treatment in Japan to treatment in their home country.Conclusion Although medical institutions can offer only a limited response, it is necessary to accumulate case examples from across the nation and prepare specific countermeasures and counselors.